3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Sunitinib
3
Trastuzumab
2
Temozolomide
2
Magnetic Resonance Spectroscopy
2
Capecitabine
2
Bortezomib
2
tovorafenib
1
tipifarnib
1
telotristat ethyl
1
surufatinib
1
sintilimab
1
selpercatinib
1
sargramostim
1
romidepsin
1
pasireotide
1
milademetan
1
lutetium Lu 177 dotatate
1
gallium Ga 68 dotatate
1
folfirinox
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
entinostat
1
copper dotatate CU-64
1
alectinib
1
aldesleukin
1
Topotecan
1
Taxes
1
TH 302
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Endocrine
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled